Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

	Gene summary
	Malignant transformation analysis
	Malignant transformation related pathway analysis
	Cell-cell communication analysis
	Single-cell gene regulatory network inference analysis
	Somatic mutation of malignant transformation related genes
	Related drugs of malignant transformation related genes

Gene: USP9X

Gene summary for USP9X

Gene summary.

Gene information	Species	Human
	Gene symbol	USP9X
	Gene ID	8239
	Gene name	ubiquitin specific peptidase 9 X-linked
	Gene Alias	DFFRX
	Cytomap	Xp11.4
	Gene Type	protein-coding
	GO ID	GO:0000003
	UniProtAcc	Q6P468

Top

Malignant transformation analysis

Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells

Malignant transformation involving gene list.

Entrez ID	Symbol	Replicates	Species	Organ	Tissue	Adj P-value	Log2FC	Malignancy
8239	USP9X	HSIL_HPV_2	Human	Cervix	HSIL_HPV	6.17e-03	2.14e-01	0.0208
8239	USP9X	CCI_1	Human	Cervix	CC	3.97e-04	7.79e-01	0.528
8239	USP9X	CCI_2	Human	Cervix	CC	4.53e-11	1.74e+00	0.5249
8239	USP9X	CCI_3	Human	Cervix	CC	1.45e-05	8.63e-01	0.516
8239	USP9X	HTA11_3410_2000001011	Human	Colorectum	AD	2.12e-06	-4.52e-01	0.0155
8239	USP9X	HTA11_347_2000001011	Human	Colorectum	AD	3.75e-09	4.71e-01	-0.1954
8239	USP9X	HTA11_866_3004761011	Human	Colorectum	AD	6.58e-05	-4.31e-01	0.096
8239	USP9X	HTA11_7696_3000711011	Human	Colorectum	AD	2.56e-02	-3.42e-01	0.0674
8239	USP9X	HTA11_6818_2000001011	Human	Colorectum	AD	3.30e-02	-3.90e-01	0.0112
8239	USP9X	HTA11_99999970781_79442	Human	Colorectum	MSS	2.15e-03	-3.10e-01	0.294
8239	USP9X	HTA11_99999965104_69814	Human	Colorectum	MSS	3.87e-12	8.39e-01	0.281
8239	USP9X	A001-C-207	Human	Colorectum	FAP	1.08e-05	-3.85e-01	0.1278
8239	USP9X	A015-C-203	Human	Colorectum	FAP	2.66e-26	-4.39e-01	-0.1294
8239	USP9X	A015-C-204	Human	Colorectum	FAP	3.03e-06	-3.75e-01	-0.0228
8239	USP9X	A014-C-040	Human	Colorectum	FAP	1.52e-04	-5.52e-01	-0.1184
8239	USP9X	A002-C-201	Human	Colorectum	FAP	1.49e-08	-3.21e-01	0.0324
8239	USP9X	A001-C-119	Human	Colorectum	FAP	1.05e-06	-4.52e-01	-0.1557
8239	USP9X	A001-C-108	Human	Colorectum	FAP	5.81e-16	-3.39e-01	-0.0272
8239	USP9X	A002-C-205	Human	Colorectum	FAP	4.79e-20	-4.12e-01	-0.1236
8239	USP9X	A001-C-104	Human	Colorectum	FAP	1.62e-02	-2.78e-01	0.0184

Page: 1 2 3 4 5 6 7 8 9 10 11

Transcriptomic changes along malignancy continuum.

Tissue	Expression Dynamics	Abbreviation
Cervix		CC: Cervix cancer
		HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions
		N_HPV: HPV-infected normal cervix
Colorectum (GSE201348)		FAP: Familial adenomatous polyposis
		CRC: Colorectal cancer
Colorectum (HTA11)		AD: Adenomas
		SER: Sessile serrated lesions
		MSI-H: Microsatellite-high colorectal cancer
		MSS: Microsatellite stable colorectal cancer
Endometrium		AEH: Atypical endometrial hyperplasia
		EEC: Endometrioid Cancer
Esophagus		ESCC: Esophageal squamous cell carcinoma
		HGIN: High-grade intraepithelial neoplasias
		LGIN: Low-grade intraepithelial neoplasias
Liver		HCC: Hepatocellular carcinoma
		NAFLD: Non-alcoholic fatty liver disease
Lung		AAH: Atypical adenomatous hyperplasia
		AIS: Adenocarcinoma in situ
		IAC: Invasive lung adenocarcinoma
		MIA: Minimally invasive adenocarcinoma
Oral Cavity		EOLP: Erosive Oral lichen planus
		LP: leukoplakia
		NEOLP: Non-erosive oral lichen planus
		OSCC: Oral squamous cell carcinoma
Prostate		BPH: Benign Prostatic Hyperplasia
Skin		AK: Actinic keratosis
		cSCC: Cutaneous squamous cell carcinoma
		SCCIS:squamous cell carcinoma in situ
Thyroid		ATC: Anaplastic thyroid cancer
		HT: Hashimoto's thyroiditis
		PTC: Papillary thyroid cancer

∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer

Figure of enriched GO biological processes.

Tissue	Disease Stage	Enriched GO biological Processes
Colorectum	AD
Colorectum	SER
Colorectum	MSS
Colorectum	MSI-H
Colorectum	FAP

∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).

Page: 1 2 3 4 5 6 7 8 9

Enriched GO biological processes.

GO ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	Count
GO:00485118	Cervix	CC	rhythmic process	65/2311	298/18723	2.79e-06	8.04e-05	65
GO:003164710	Cervix	CC	regulation of protein stability	63/2311	298/18723	1.14e-05	2.45e-04	63
GO:00160498	Cervix	CC	cell growth	92/2311	482/18723	1.16e-05	2.49e-04	92
GO:00615647	Cervix	CC	axon development	89/2311	467/18723	1.71e-05	3.27e-04	89
GO:005082110	Cervix	CC	protein stabilization	43/2311	191/18723	5.90e-05	8.54e-04	43
GO:00076238	Cervix	CC	circadian rhythm	46/2311	210/18723	6.76e-05	9.60e-04	46
GO:00074097	Cervix	CC	axonogenesis	78/2311	418/18723	1.14e-04	1.43e-03	78
GO:00071786	Cervix	CC	transmembrane receptor protein serine/threonine kinase signaling pathway	67/2311	355/18723	2.39e-04	2.67e-03	67
GO:00715595	Cervix	CC	response to transforming growth factor beta	50/2311	256/18723	6.31e-04	5.91e-03	50
GO:00715605	Cervix	CC	cellular response to transforming growth factor beta stimulus	49/2311	250/18723	6.55e-04	6.05e-03	49
GO:00605606	Cervix	CC	developmental growth involved in morphogenesis	46/2311	234/18723	8.82e-04	7.63e-03	46
GO:00510528	Cervix	CC	regulation of DNA metabolic process	65/2311	359/18723	9.25e-04	7.84e-03	65
GO:00486756	Cervix	CC	axon extension	26/2311	120/18723	2.80e-03	1.87e-02	26
GO:19901385	Cervix	CC	neuron projection extension	34/2311	172/18723	3.52e-03	2.27e-02	34
GO:00071795	Cervix	CC	transforming growth factor beta receptor signaling pathway	38/2311	198/18723	3.62e-03	2.31e-02	38
GO:19900006	Cervix	CC	amyloid fibril formation	10/2311	34/18723	6.40e-03	3.58e-02	10
GO:00485886	Cervix	CC	developmental cell growth	42/2311	234/18723	7.88e-03	4.15e-02	42
GO:00711083	Cervix	CC	protein K48-linked deubiquitination	10/2311	35/18723	7.99e-03	4.18e-02	10
GO:003164715	Cervix	HSIL_HPV	regulation of protein stability	31/737	298/18723	8.69e-07	4.19e-05	31
GO:005082115	Cervix	HSIL_HPV	protein stabilization	21/737	191/18723	2.17e-05	6.58e-04	21

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24

Enriched KEGG pathways.

Pathway ID

Tissue

Disease Stage

Description

Gene Ratio

Bg Ratio

pvalue

p.adjust

qvalue

Count

Page: 1

Top

Cell-cell communication analysis

Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states

Ligand

Receptor

LRpair

Pathway

Tissue

Disease Stage

Page: 1

Top

Single-cell gene regulatory network inference analysis

Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states

Cell Type

Tissue

Disease Stage

Target Gene

RSS

Regulon Activity

∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.

Page: 1

Top

Somatic mutation of malignant transformation related genes

Annotation of somatic variants for genes involved in malignant transformation

Hugo Symbol

Variant Class

Variant Classification

dbSNP RS

HGVSc

HGVSp

HGVSp Short

SWISSPROT

BIOTYPE

SIFT

PolyPhen

Tumor Sample Barcode

Tissue

Histology

Sex

Age

Stage

Therapy Types

Drugs

Outcome

USP9X

SNV

Missense_Mutation

c.1252N>T

p.Arg418Cys

p.R418C

Q93008

protein_coding

deleterious(0)

probably_damaging(0.999)

TCGA-BS-A0UF-01

Endometrium

uterine corpus endometrioid carcinoma

Female

>=65

I/II

Unknown

USP9X

SNV

Missense_Mutation

novel

c.4556N>C

p.Ile1519Thr

p.I1519T

Q93008

protein_coding

tolerated(0.07)

benign(0.03)

TCGA-BS-A0UF-01

Endometrium

uterine corpus endometrioid carcinoma

Female

>=65

I/II

Unknown

USP9X

SNV

Missense_Mutation

c.5555N>C

p.Gln1852Pro

p.Q1852P

Q93008

protein_coding

tolerated(0.18)

benign(0)

TCGA-BS-A0UF-01

Endometrium

uterine corpus endometrioid carcinoma

Female

>=65

I/II

Unknown

USP9X

SNV

Missense_Mutation

c.3758C>T

p.Ser1253Leu

p.S1253L

Q93008

protein_coding

tolerated(0.49)

benign(0.001)

TCGA-BS-A0UV-01

Endometrium

uterine corpus endometrioid carcinoma

Female

<65

III/IV

Unknown

USP9X

SNV

Missense_Mutation

novel

c.1196N>C

p.Val399Ala

p.V399A

Q93008

protein_coding

deleterious(0)

benign(0.296)

TCGA-D1-A175-01

Endometrium

uterine corpus endometrioid carcinoma

Female

<65

I/II

Chemotherapy

paclitaxel

USP9X

SNV

Missense_Mutation

novel

c.4561N>A

p.Asp1521Asn

p.D1521N

Q93008

protein_coding

tolerated(0.72)

benign(0.003)

TCGA-D1-A175-01

Endometrium

uterine corpus endometrioid carcinoma

Female

<65

I/II

Chemotherapy

paclitaxel

USP9X

SNV

Missense_Mutation

novel

c.5224N>A

p.Val1742Ile

p.V1742I

Q93008

protein_coding

tolerated(0.17)

benign(0.343)

TCGA-D1-A175-01

Endometrium

uterine corpus endometrioid carcinoma

Female

<65

I/II

Chemotherapy

paclitaxel

USP9X

SNV

Missense_Mutation

c.1507N>G

p.Met503Val

p.M503V

Q93008

protein_coding

deleterious(0)

possibly_damaging(0.778)

TCGA-D1-A177-01

Endometrium

uterine corpus endometrioid carcinoma

Female

>=65

I/II

Unknown

USP9X

SNV

Missense_Mutation

novel

c.2356N>C

p.Ala786Pro

p.A786P

Q93008

protein_coding

deleterious(0)

possibly_damaging(0.886)

TCGA-D1-A17Q-01

Endometrium

uterine corpus endometrioid carcinoma

Female

<65

I/II

Unknown

USP9X

SNV

Missense_Mutation

novel

c.5602N>A

p.Val1868Met

p.V1868M

Q93008

protein_coding

tolerated(0.07)

benign(0.438)

TCGA-DF-A2KU-01

Endometrium

uterine corpus endometrioid carcinoma

Female

Unknown

I/II

Unknown

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31

Top

Related drugs of malignant transformation related genes

Identification of chemicals and drugs interact with genes involved in malignant transfromation

(DGIdb 4.0)

Entrez ID

Symbol

Category

Interaction Types

Drug Claim Name

Drug Name

PMIDs

Page: 1